Division of Neuromuscular Diseases and Clinical Neurophysiology Laboratories, Department of Neurology, Icahn School of Medicine, Mount Sinai Hospital, 1468 Madison Avenue, New York, NY, 10029, USA.
Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
J Neurovirol. 2020 Oct;26(5):797-799. doi: 10.1007/s13365-020-00884-7. Epub 2020 Jul 27.
There is concern that the global burden of coronavirus disease of 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection might yield an increased occurrence of Guillain-Barré syndrome (GBS). It is currently unknown whether concomitant SARS-CoV-2 infection and GBS are pathophysiologically related, what biomarkers are useful for diagnosis, and what is the optimal treatment given the medical comorbidities, complications, and simultaneous infection. We report a patient who developed severe GBS following SARS-CoV-2 infection at the peak of the initial COVID-19 surge (April 2020) in New York City and discuss diagnostic and management issues and complications that may warrant special consideration in similar patients.
人们担心，由严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）感染引起的 2019 年冠状病毒病（COVID-19）全球负担可能导致格林-巴利综合征（GBS）的发生率增加。目前尚不清楚同时发生的 SARS-CoV-2 感染和 GBS 是否与病理生理学有关，哪些生物标志物有助于诊断，以及鉴于合并症、并发症和同时感染，最佳治疗方法是什么。我们报告了一名患者，他在纽约市 COVID-19 首次爆发高峰期（2020 年 4 月）感染 SARS-CoV-2 后出现严重 GBS，并讨论了诊断和管理问题以及并发症，这些问题可能需要在类似患者中特别考虑。
